Health Condition 1: I60-I69- Cerebrovascular diseases
Conditions
Interventions
Intervention1: autologous bone marrow derived stem cells: After the baseline assessment 1 to 2 million of Bone Marrow Mononuclear Cells (BMNCs) per kg body weight will be administered intravenously th
Sponsors
Indian Council of Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with ischemic stroke within 1.5 months to 1 year of index event 2. Age:18-65 years 3. MRC of hand and wrist muscles between 1-3. 4. Brunnstrom stage (3-5) 5. Subjects/ care givers agreed in writing that they will be participating in clinical research, as viewed from the legal representative (patient).
Exclusion criteria
Exclusion criteria: 1. Active Infection 2. Immunocompromised state history or laboratory results indicative of any significant cardiac, endocrine, hematologic, hepatic, renal, or other disorders 3. Neoplastic diseases ; malignancy 4. Autoimmune disorders 5. Immune-compromised subjects 6. Progressive neurological worsening 7. Contraindication to MRI 8. Female patients with known pregnancy or at risk of pregnancy, positive urine pregnancy test at screening. 9. Any other reason that, in the opinion of the Principal Investigator, makes the participant unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic potential of autologous bone marrow derived mononuclear stem cells (BMMNC) infusion in chronic stroke. To study upregulation of growth factors (BDNF & VEGF) after BM-MNC infusion in chronic stroke.Timepoint: Baseline, 6 weeks, 24 weeks and 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactDr Ashu Bhasin
AIIMS New Delhi
Outcome results
None listed